Table 2.

Comparison of the four published case reports of Lumason-induced anaphylaxis.

Patient Factors	Olson et al. 201820	Mansour et al. 202221	Coudray et al. 201722	Kerber et al. 202223	Mikhail et al. 2022
Age	63	67	62	47	50
Sex	Male	Male	Male	Female	Male
Comorbidities	Myelodysplastic syndrome, systemic mastocytosis	Heart failure with preserved ejection fraction (HFpEF)	Hypertension	Not known	Hypertension, atrial fibrillation, pericardial effusion, obstructive sleep apnea, diabetes mellitus type 2, asthma
Other allergies	NKDA	NKDA	NKDA	NKDA	NKDA
Diagnostic test	Ultrasound-guided biopsy of hepatic mass	Outpatient echocardiogram to evaluate worsening dyspnea on exertion	Control at 6 months for ongoing surveillance post-EVAR	Echo stress test	Transthoracic echocardiogram for stroke workup
Reaction	Apnea and pulseless electrical activity within 30 s of administration of Lumason	Severe anaphylactic shock immediately following administration of Lumason	Limb paresthesia, shortness of breath, rash, profuse sweating, loss of consciousness, urination, and severe hypotension within 30 s of administration of SonoVue	Nausea, vomiting, diarrhea, hypotension and hypoxia within 60 s of administration of Lumason	Shortness of breath, diaphoresis, cyanosis, hypoxia, tachycardia following administration of Lumason
Intervention	Immediate initiation of CPR with administration of epinephrine; Return of spontaneous circulation achieved after 4 min	Intravenous antihistamines, methylprednisolone and epinephrine were administered followed by transfer to emergency room for monitoring	Immediate transfer to ICU, injection of corticosteroids and antihistamines, normal saline, oxygen, and epinephrine	Epinephrine, dexamethasone, benadryl, oxygen and eventual transfer to ICU	Solumedrol, Albuterol, Diphenhydramine, and oxygen